
抗人 SUMF2 抗体对
01AB00962
Sulfatase modifying factor 2 (SUMF2) is a protein encoded by the SUMF2 gene in humans. It is a member of the sulfatase-modifying factor family and localizes to the lumen of the endoplasmic reticulum. SUMF2 contains a DUF323 domain and exhibits low levels of formylglycine-generating activity. It can heterodimerize with SUMF1, a protein with high formylglycine-generating activity. SUMF2 plays a role in regulating sulfatase activities by competing with SUMF1 for the same substrate. The protein is involved in the post-translational modification of sulfatases, which is essential for their catalytic activity. In terms of disease associations, SUMF2 has been linked to urothelial carcinoma, where high SUMF2 expression correlates with poor overall survival and disease-free survival in bladder cancer patients. Additionally, SUMF2 amplification has been observed in urothelial carcinoma tissues.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- SUMF2
- 蛋白别名
- sulfatase modifying factor 2; SUMF2
- UniProt
- Q8NBJ7
- 物种
- Human
产品详情
- 靶点名称
- SUMF2
- 蛋白名称
- sulfatase modifying factor 2
- 蛋白别名
- Inactive C-alpha-formylglycine-generating enzyme 2; Paralog of formylglycine-generating enzyme; pFGE; Sulfatase-modifying factor 2
- 靶点基因名
- SUMF2
- UniProt
- Q8NBJ7
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Sulfatase modifying factor 2 (SUMF2) is a protein encoded by the SUMF2 gene in humans. It is a member of the sulfatase-modifying factor family and localizes to the lumen of the endoplasmic reticulum. SUMF2 contains a DUF323 domain and exhibits low levels of formylglycine-generating activity. It can heterodimerize with SUMF1, a protein with high formylglycine-generating activity. SUMF2 plays a role in regulating sulfatase activities by competing with SUMF1 for the same substrate. The protein is involved in the post-translational modification of sulfatases, which is essential for their catalytic activity. In terms of disease associations, SUMF2 has been linked to urothelial carcinoma, where high SUMF2 expression correlates with poor overall survival and disease-free survival in bladder cancer patients. Additionally, SUMF2 amplification has been observed in urothelial carcinoma tissues.